Lydie Lemonnier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lydie Lemonnier has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Pagin
CHU Lille, Service de Toxicologie et Génopathies, 59000 Lille, France
4 shared publications C. Bareil
Génétique Moléculaire, CHU Montpellier, Montpellier, France
4 shared publicationsC. Mekki
AP-HP, Département de Biochimie-Biologie Moléculaire, Pharmacologie, Génétique Médicale, Hôpital Henri Mondor, Créteil F-94010, France
4 shared publicationsE. Girodon
Service de Médecine Génomique des Maladies de Système et d'Organe, APHP Centre - Université de Paris, Hôpital Cochin, Paris, France; INSERM U1151, Institut Necker Enfants Malades, Université de Paris, Paris, France
4 shared publicationsG. Lalau
Biochimie et Biologie Moléculaire, CHU Lille, Lille, France
4 shared publicationsM. Claustres
Université de Montpellier, Montpellier, France
4 shared publications
Latest Publications
- 23 December 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (3) , 515-524
The multi-faceted nature of 15 CFTR exonic variations: Impact on their functional classification and perspectives for therapy
- 23 December 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (3) , 515-524
The multi-faceted nature of 15 CFTR exonic variations: Impact on their functional classification and perspectives for therapy
- 1 January 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (1) , 88-95
Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis
- 1 January 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (1) , 88-95
Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis
- Open Access
- 10 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3624
First Wave of COVID-19 in French Patients with Cystic Fibrosis
Viral infections are known to lead to serious respiratory complications in cystic fibrosis (CF) patients. Hypothesizing that CF patients were a population at high risk for severe respiratory complications from SARS-CoV-2 infection, we conducted a national study to describe the clinical expression of COVID-19 in French CF patients. This prospective observational study involves all 47 French CF centers caring for approximately 7500 CF patients. Between March 1st and June 30th 2020, 31 patients were diagnosed with COVID-19: 19 had positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs; 1 had negative RT-PCR but typical COVID-19 signs on a CT scan; and 11 had positive SARS-CoV-2 serology. Fifteen were males, median (range) age was 31 (9–60) years, and 12 patients were living with a lung transplant. The majority of the patients had CF-related diabetes (n = 19, 61.3%), and a mild lung disease (n = 19, 65%, with percent-predicted forced expiratory volume in 1 s (ppFEV1) > 70). Three (10%) patients remained asymptomatic. For the 28 (90%) patients who displayed symptoms, most common symptoms at admission were fever (n = 22, 78.6%), fatigue (n = 14, 50%), and increased cough (n = 14, 50%). Nineteen were hospitalized (including 11 out of the 12 post-lung transplant patients), seven required oxygen therapy, and four (3 post-lung transplant patients) were admitted to an Intensive Care Unit (ICU). Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were discharged home without noticeable short-term sequelae. Overall, French CF patients were rarely diagnosed with COVID-19. Further research should establish whether they were not infected or remained asymptomatic upon infection. In diagnosed cases, the short-term evolution was favorable with rare acute respiratory distress syndrome and no death. Post-lung transplant patients had more severe outcomes and should be monitored more closely.
- 10 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3624
Open AccessFirst Wave of COVID-19 in French Patients with Cystic Fibrosis
Viral infections are known to lead to serious respiratory complications in cystic fibrosis (CF) patients. Hypothesizing that CF patients were a population at high risk for severe respiratory complications from SARS-CoV-2 infection, we conducted a national study to describe the clinical expression of COVID-19 in French CF patients. This prospective observational study involves all 47 French CF centers caring for approximately 7500 CF patients. Between March 1st and June 30th 2020, 31 patients were diagnosed with COVID-19: 19 had positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs; 1 had negative RT-PCR but typical COVID-19 signs on a CT scan; and 11 had positive SARS-CoV-2 serology. Fifteen were males, median (range) age was 31 (9–60) years, and 12 patients were living with a lung transplant. The majority of the patients had CF-related diabetes (n = 19, 61.3%), and a mild lung disease (n = 19, 65%, with percent-predicted forced expiratory volume in 1 s (ppFEV1) > 70). Three (10%) patients remained asymptomatic. For the 28 (90%) patients who displayed symptoms, most common symptoms at admission were fever (n = 22, 78.6%), fatigue (n = 14, 50%), and increased cough (n = 14, 50%). Nineteen were hospitalized (including 11 out of the 12 post-lung transplant patients), seven required oxygen therapy, and four (3 post-lung transplant patients) were admitted to an Intensive Care Unit (ICU). Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were discharged home without noticeable short-term sequelae. Overall, French CF patients were rarely diagnosed with COVID-19. Further research should establish whether they were not infected or remained asymptomatic upon infection. In diagnosed cases, the short-term evolution was favorable with rare acute respiratory distress syndrome and no death. Post-lung transplant patients had more severe outcomes and should be monitored more closely.
- 1 June 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S61-S62
P017 Update of CFTR-France: toward a more relevant dataset for predicting the impact of rare CFTR variants
- 1 June 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S61-S62
P017 Update of CFTR-France: toward a more relevant dataset for predicting the impact of rare CFTR variants
- Open Access
- 3 August 2018
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 15 (8) , 1644
Recommendations for Improving the Quality of Rare Disease Registries
Rare diseases (RD) patient registries are powerful instruments that help develop clinical research, facilitate the planning of appropriate clinical trials, improve patient care, and support healthcare management. They constitute a key information system that supports the activities of European Reference Networks (ERNs) on rare diseases. A rapid proliferation of RD registries has occurred during the last years and there is a need to develop guidance for the minimum requirements, recommendations and standards necessary to maintain a high-quality registry. In response to these heterogeneities, in the framework of RD-Connect, a European platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research, we report on a list of recommendations, developed by a group of experts, including members of patient organizations, to be used as a framework for improving the quality of RD registries. This list includes aspects of governance, Findable, Accessible, Interoperable and Reusable (FAIR) data and information, infrastructure, documentation, training, and quality audit. The list is intended to be used by established as well as new RD registries. Further work includes the development of a toolkit to enable continuous assessment and improvement of their organizational and data quality.
- 3 August 2018
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 15 (8) , 1644
Open AccessRecommendations for Improving the Quality of Rare Disease Registries
Rare diseases (RD) patient registries are powerful instruments that help develop clinical research, facilitate the planning of appropriate clinical trials, improve patient care, and support healthcare management. They constitute a key information system that supports the activities of European Reference Networks (ERNs) on rare diseases. A rapid proliferation of RD registries has occurred during the last years and there is a need to develop guidance for the minimum requirements, recommendations and standards necessary to maintain a high-quality registry. In response to these heterogeneities, in the framework of RD-Connect, a European platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research, we report on a list of recommendations, developed by a group of experts, including members of patient organizations, to be used as a framework for improving the quality of RD registries. This list includes aspects of governance, Findable, Accessible, Interoperable and Reusable (FAIR) data and information, infrastructure, documentation, training, and quality audit. The list is intended to be used by established as well as new RD registries. Further work includes the development of a toolkit to enable continuous assessment and improvement of their organizational and data quality.
- Open Access
- 1 June 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15, S52
4 Valuable collaboration between a molecular CFTR database and a national CF registry: the French experience
- 1 June 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15, S52
Open Access4 Valuable collaboration between a molecular CFTR database and a national CF registry: the French experience
- 1 March 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15 (2) , 204-212
Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!
- 1 March 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15 (2) , 204-212
Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!